Cargando…

Immunotherapy in glioblastoma treatment: Current state and future prospects

Glioblastoma remains as the most common and aggressive malignant brain tumor, standing with a poor prognosis and treatment prospective. Despite the aggressive standard care, such as surgical resection and chemoradiation, median survival rates are low. In this regard, immunotherapeutic strategies aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocha Pinheiro, Samuel Luca, Lemos, Fabian Fellipe Bueno, Marques, Hanna Santos, Silva Luz, Marcel, de Oliveira Silva, Luís Guilherme, Faria Souza Mendes dos Santos, Clara, da Costa Evangelista, Karolaine, Calmon, Mariana Santos, Sande Loureiro, Matheus, Freire de Melo, Fabrício
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134201/
https://www.ncbi.nlm.nih.gov/pubmed/37124134
http://dx.doi.org/10.5306/wjco.v14.i4.138
Descripción
Sumario:Glioblastoma remains as the most common and aggressive malignant brain tumor, standing with a poor prognosis and treatment prospective. Despite the aggressive standard care, such as surgical resection and chemoradiation, median survival rates are low. In this regard, immunotherapeutic strategies aim to become more attractive for glioblastoma, considering its recent advances and approaches. In this review, we provide an overview of the current status and progress in immunotherapy for glioblastoma, going through the fundamental knowledge on immune targeting to promising strategies, such as Chimeric antigen receptor T-Cell therapy, immune checkpoint inhibitors, cytokine-based treatment, oncolytic virus and vaccine-based techniques. At last, it is discussed innovative methods to overcome diverse challenges, and future perspectives in this area.